These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

579 related articles for article (PubMed ID: 16754836)

  • 1. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.
    Olincy A; Harris JG; Johnson LL; Pender V; Kongs S; Allensworth D; Ellis J; Zerbe GO; Leonard S; Stevens KE; Stevens JO; Martin L; Adler LE; Soti F; Kem WR; Freedman R
    Arch Gen Psychiatry; 2006 Jun; 63(6):630-8. PubMed ID: 16754836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Schizophrenia and the alpha7 nicotinic acetylcholine receptor.
    Martin LF; Freedman R
    Int Rev Neurobiol; 2007; 78():225-46. PubMed ID: 17349863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia.
    Zhang XY; Liu L; Liu S; Hong X; Chen DC; Xiu MH; Yang FD; Zhang Z; Zhang X; Kosten TA; Kosten TR
    Am J Psychiatry; 2012 Sep; 169(9):974-81. PubMed ID: 22952075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial phase 2 trial of a nicotinic agonist in schizophrenia.
    Freedman R; Olincy A; Buchanan RW; Harris JG; Gold JM; Johnson L; Allensworth D; Guzman-Bonilla A; Clement B; Ball MP; Kutnick J; Pender V; Martin LF; Stevens KE; Wagner BD; Zerbe GO; Soti F; Kem WR
    Am J Psychiatry; 2008 Aug; 165(8):1040-7. PubMed ID: 18381905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. α7-nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia.
    Freedman R
    Annu Rev Med; 2014; 65():245-61. PubMed ID: 24111888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia.
    Tregellas JR; Tanabe J; Rojas DC; Shatti S; Olincy A; Johnson L; Martin LF; Soti F; Kem WR; Leonard S; Freedman R
    Biol Psychiatry; 2011 Jan; 69(1):7-11. PubMed ID: 20728875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic Limitations on Effects of an Alpha7-Nicotinic Receptor Agonist in Schizophrenia: Randomized Trial with an Extended-Release Formulation.
    Kem WR; Olincy A; Johnson L; Harris J; Wagner BD; Buchanan RW; Christians U; Freedman R
    Neuropsychopharmacology; 2018 Feb; 43(3):583-589. PubMed ID: 28825423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders.
    Roncarati R; Scali C; Comery TA; Grauer SM; Aschmi S; Bothmann H; Jow B; Kowal D; Gianfriddo M; Kelley C; Zanelli U; Ghiron C; Haydar S; Dunlop J; Terstappen GC
    J Pharmacol Exp Ther; 2009 May; 329(2):459-68. PubMed ID: 19223665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.
    Olincy A; Stevens KE
    Biochem Pharmacol; 2007 Oct; 74(8):1192-201. PubMed ID: 17714692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DMXB (GTS-21) ameliorates the cognitive deficits in beta amyloid(25-35(-) ) injected mice through preventing the dysfunction of alpha7 nicotinic receptor.
    Chen L; Wang H; Zhang Z; Li Z; He D; Sokabe M; Chen L
    J Neurosci Res; 2010 Jun; 88(8):1784-94. PubMed ID: 20127813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia.
    Martin LF; Kem WR; Freedman R
    Psychopharmacology (Berl); 2004 Jun; 174(1):54-64. PubMed ID: 15205879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function.
    Swerdlow NR; Light GA; Cadenhead KS; Sprock J; Hsieh MH; Braff DL
    Arch Gen Psychiatry; 2006 Dec; 63(12):1325-35. PubMed ID: 17146007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study.
    Winterer G; Gallinat J; Brinkmeyer J; Musso F; Kornhuber J; Thuerauf N; Rujescu D; Favis R; Sun Y; Franc MA; Ouwerkerk-Mahadevan S; Janssens L; Timmers M; Streffer JR
    Neuropharmacology; 2013 Jan; 64():197-204. PubMed ID: 22766391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The nicotinic α7 receptor agonist GTS-21 improves cognitive performance in ketamine impaired rhesus monkeys.
    Cannon CE; Puri V; Vivian JA; Egbertson MS; Eddins D; Uslaner JM
    Neuropharmacology; 2013 Jan; 64():191-6. PubMed ID: 22659472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The selective nicotinic acetylcholine receptor alpha7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain.
    Feuerbach D; Lingenhoehl K; Olpe HR; Vassout A; Gentsch C; Chaperon F; Nozulak J; Enz A; Bilbe G; McAllister K; Hoyer D
    Neuropharmacology; 2009 Jan; 56(1):254-63. PubMed ID: 18793655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurocognitive deficits in schizophrenia are associated with alterations in blood levels of neurosteroids: a multiple regression analysis of findings from a double-blind, randomized, placebo-controlled, crossover trial with DHEA.
    Ritsner MS; Strous RD
    J Psychiatr Res; 2010 Jan; 44(2):75-80. PubMed ID: 19665142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DMXB, an alpha7 nicotinic agonist, normalizes auditory gating in isolation-reared rats.
    O'Neill HC; Rieger K; Kem WR; Stevens KE
    Psychopharmacology (Berl); 2003 Sep; 169(3-4):332-9. PubMed ID: 12759805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.
    Keefe RS; Meltzer HA; Dgetluck N; Gawryl M; Koenig G; Moebius HJ; Lombardo I; Hilt DC
    Neuropsychopharmacology; 2015 Dec; 40(13):3053-60. PubMed ID: 26089183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of nicotine on the amplitude and gating of the auditory P50 and its influence by dopamine D2 receptor gene polymorphism.
    Knott V; Millar A; Fisher D; Albert P
    Neuroscience; 2010 Mar; 166(1):145-56. PubMed ID: 19961902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.